Quarterly ResultMay 7, 2026, 04:14 PM
REVB Q1 Net Loss Attributable to Common Stockholders $8.69M; Going Concern Doubt
AI Summary
Revelation Biosciences reported a net loss attributable to common stockholders of $8.69 million for Q1 2026, significantly higher than $2.05 million in Q1 2025, driven by increased operating expenses and deemed dividends from warrant inducements. Despite raising approximately $6.7 million in net proceeds from Class I Warrant Inducement exercises, the company's recurring losses and negative cash flow raise substantial doubt about its ability to continue as a going concern, with current cash not expected to sustain operations for a year. The company plans to seek additional capital.
Key Highlights
- Net loss attributable to common stockholders increased to $8.69 million in Q1 2026 from $2.05 million in Q1 2025.
- Total operating expenses rose to $3.09 million in Q1 2026 from $2.09 million in Q1 2025.
- Cash and cash equivalents increased to $14.11 million as of March 31, 2026, from $10.70 million at December 31, 2025.
- Net cash provided by financing activities was $6.70 million in Q1 2026, primarily from warrant exercises.
- Accumulated deficit reached $52.43 million as of March 31, 2026.
- The company's ability to continue as a going concern is in substantial doubt due to recurring losses and insufficient cash.
- Effected a 1-for-4 reverse stock split on January 28, 2026.
- Class I Warrant Inducement generated $6.7 million in net proceeds and triggered $5.7 million in deemed dividends.